Growth opportunity Acquired by Brookfield and La Caisse in 2025 and recently appointing a new CEO in Jan 2026, Antylia Scientific is positioned for strategic expansion and potential upsell of high-value consumables, testing equipment, and bioprocessing solutions to larger enterprise accounts.

Strategic markets Global diagnostics, environmental testing, and life sciences labs comprise core markets with steady demand for molecular diagnostic reagents, specialty chemicals, water and air quality testing gear, and related laboratory products—opportunities to expand bundled solutions.

High-value customers Revenue range and notable funding indicate mid to large lab networks and research institutions as primary targets for portfolio offerings, including critical lab consumables, equipment, and smart purchasing technologies.

Tech-enabled sales Existing tech stack including DocuSign and analytics tools suggests readiness for streamlined procurement, contract management, and repeatable ordering processes to improve win rates and cross-sell of complementary products.

Leadership continuity Recent C-suite change coupled with historical leadership transitions signals potential for renewed sales engagements, channel partnerships, and executive sponsor outreach to accelerate long-term contracts and strategic accounts.